Literature DB >> 33356049

Tocilizumab in Covid-19.

David E Leaf1, Shruti Gupta1, Wei Wang1.   

Abstract

Entities:  

Year:  2020        PMID： 33356049     DOI： 10.1056/NEJMc2032911

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

Review 1.  Autoinflammatory Diseases and Cytokine Storms-Imbalances of Innate and Adaptative Immunity.

Authors:  Annalisa Marcuzzi; Elisabetta Melloni; Giorgio Zauli; Arianna Romani; Paola Secchiero; Natalia Maximova; Erika Rimondi
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

Review 2.  Mechanisms of Immunothrombosis by SARS-CoV-2.

Authors:  María Teresa Hernández-Huerta; Alma Dolores Pérez-Santiago; Laura Pérez-Campos Mayoral; Luis Manuel Sánchez Navarro; Francisco Javier Rodal Canales; Abraham Majluf-Cruz; Carlos Alberto Matias-Cervantes; Eduardo Pérez-Campos Mayoral; Carlos Romero Díaz; Gabriel Mayoral-Andrade; Margarito Martínez Cruz; Judith Luna Ángel; Eduardo Pérez-Campos
Journal:  Biomolecules       Date:  2021-10-20

3.  Hyper-inflammatory responses in COVID-19 and anti-inflammatory therapeutic approaches.

Authors:  Hojun Choi; Eui-Cheol Shin
Journal:  BMB Rep       Date:  2022-01       Impact factor: 5.041

4.  Clinical outcomes in patients with COVID-19 and gynecologic cancer: A society of gynecologic oncology COVID-19 and gynecologic cancer registry study.

Authors:  Gretchen E Glaser; Olivia D Lara; Bhavana Pothuri; Carolina Gomez Grimaldi; Lauren S Prescott; Spyridon A Mastroyannis; Sarah Kim; Adam C ElNaggar; Diogo Torres; Lesley B Conrad; Michaela McGree; Amy Weaver; Warner K Huh; David E Cohn; S Diane Yamada; Amanda N Fader
Journal:  Gynecol Oncol       Date:  2022-09-22       Impact factor: 5.304

Review 5.  Therapeutic advances in COVID-19.

Authors:  Naoka Murakami; Robert Hayden; Thomas Hills; Hanny Al-Samkari; Jonathan Casey; Lorenzo Del Sorbo; Patrick R Lawler; Meghan E Sise; David E Leaf
Journal:  Nat Rev Nephrol       Date:  2022-10-17       Impact factor: 42.439

6.  Tocilizumab in COVID-19: some clarity amid controversy.

Authors:  Shruti Gupta; David E Leaf
Journal:  Lancet       Date:  2021-05-01       Impact factor: 79.321

7.  Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study.

Authors:  Thais G Moreira; Kimble T F Matos; Giovana S De Paula; Thais M M Santana; Raquel G Da Mata; Fernando C Pansera; Andre S Cortina; Marcelle G Spinola; Clare M Baecher-Allan; Gerson D Keppeke; Jules Jacob; Vaseem Palejwala; Karen Chen; Saef Izzy; Brian C Healey; Rafael M Rezende; Rogerio A Dedivitis; Kunwar Shailubhai; Howard L Weiner
Journal:  Front Immunol       Date:  2021-08-12       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.